Mizuho reiterated its bullish stance on biotech Neumora Therapeutics Inc. on Wednesday, and predicted a positive outcome when ...

Aurobindo Pharma’s revenue was in-line with our estimates ... We revise our rating to “BUY” from “ACCUMULATE” based on the ...

Shares of EyePoint Pharmaceuticals (EYPT) have gained 12.5% over the past ... You can see the complete list of today's Zacks Rank #1 (Strong Buy) stocks here >>>> Therefore, while the consensus price ...

The clinical-stage biopharmaceutical company named Julie Eastland as chief executive officer, president and director. She succeeds Kimberly Blackwell, who will remain as a strategic advisor to the ...

With the FDA's acceptance of Urogen's NDA and issuance of an 06/13/2025 PDUFA the clock is now ticking for FDA approval of ...

Vertex has reached a key moment because the U.S. Food and Drug Administration (FDA) is reviewing its candidate, suzetrigine, ...

The health-tech industry’s long-term growth is fueled by the growing need for cutting-edge technologies to address critical ...

Bank of America Securities analyst Jason Zemansky maintained a Buy rating on Rocket Pharmaceuticals (RCKT – Research Report) today. The ...

This article highlights 10 affordable healthcare stocks that investors might consider adding to their portfolios. Each of ...

Since its approval in mid-March of 2024, sales of Rezdiffra are increasing expediciously, reaching $62.2 million in Q3, the drug's first full quarter on the market. A mere year ago, Madrigal had no ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...